Kenvue Inc. Common Stock (NY:KVUE)

17.39 +0.19 (+1.10%)

Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kenvue Inc. Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

30 31 Next >

Why Is Kenvue Stock Falling, and Is It a Buying Opportunity? ↗

October 07, 2025

Investors are interested in this beaten-down business.

Via The Motley Fool

Options Corner: Despite Political Woes, Kenvue Can Still Make Tylenol Great Again ↗

October 06, 2025

While Kenvue's Tylenol has attracted intense political pressure, speculators are determined to make KVUE stock great again.

Via Benzinga

A Congress Member Sold Up To $330K In UnitedHealth Group Stock: Here's What You Need To Know ↗

October 06, 2025

Via Benzinga

Should You Buy Kenvue Stock After Its 30% Plunge? ↗

October 01, 2025

There hasn't been much good news lately for this Johnson & Johnson spinoff.

Via The Motley Fool

Topics Government Lawsuit

Cullen Trims KVUE Stake With $149.5M Share Sale ↗

October 01, 2025

Via The Motley Fool

Topics Regulatory Compliance

Kenvue Stock To Face More Headwinds? Trump’s Tylenol Warning Revives Autism Lawsuits, Retail Bulls Stay Unfazed ↗

September 24, 2025

Via Stocktwits

Topics Government Lawsuit

Why Is Kenvue Stock Rising Premarket Today? ↗

September 24, 2025

Via Stocktwits

Why Is Kenvue Stock Rising Today? ↗

September 23, 2025

Via Stocktwits

Friday's session: most active stock in the S&P500 index ↗

September 26, 2025

Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Friday and discover the stocks that are dominating the trading activity and setting the pace for...

Via Chartmill

Demystifying Kenvue: Insights From 11 Analyst Reviews ↗

September 26, 2025

Kenvue (NYSE: KVUE) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. In the table below, you'll find a summary of their recent ratings,...

Via Benzinga

White House Highlights A Controversial 2017 Tylenol Tweet On Its Usage During Pregnancy: 'We Actually Don't Recommend...' ↗

September 26, 2025

A 2017 post by Tylenol on X (formerly Twitter) highlighted by White House has fueled a buzz around President Donald Trump‘s claim that the drug is linked with autism in kids.

Via Benzinga

Kenvue Bounces Off Record Low: A Deep Dive into its Rebound and Future Prospects

September 24, 2025

Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has experienced a significant rebound in its stock price, climbing notably from a recent record low. This resurgence...

Via MarketMinute

Topics Government Product Recall

Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish ↗

September 22, 2025

Via Stocktwits

Topics Government

Kenvue Shares Drop Ahead Of Trump’s ‘Biggest Announcement’ On Autism: Reports Say Administration To Link Tylenol With Risk Of Disease ↗

September 22, 2025

Via Stocktwits

Topics Government

What's going on in today's session: S&P500 movers ↗

September 24, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Wednesday's session: most active stock in the S&P500 index ↗

September 24, 2025

Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace...

Via Chartmill

Kenvue Surges Over 2% Pre-Market Despite Trump Administration's Autism Warning ↗

September 24, 2025

Kenvue's stock rose 2.61% to $17.69 in pre-market trading on Wednesday, despite concerns sparked by President Trump's comments linking acetaminophen to autism.

Via Benzinga

Topics Government

Jon Stewart Roasts Trump Over 'Acetaminophen' Pronunciation: 'We Would Like A Second Opinion' ↗

September 24, 2025

Trump struggles to pronounce acetaminophen while warning pregnant women of its potential link to autism. Jon Stewart mocks his incompetence.

Via Benzinga

Topics Government

Nvidia, Plug Power, Micron, Kenvue, Kroger: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗

September 23, 2025

Micron stock showed a muted reaction to earnings despite the quarterly numbers and guidance exceeding expectations.

Via Stocktwits

Topics Artificial Intelligence

Trump’s Tylenol Warning Sparks FDA Action, But Kenvue Stock Climbs: Retail Traders See ‘Huge Buying Opportunity’ ↗

September 23, 2025

Kenvue is facing renewed litigation risks, activist investor pressure, and a challenging consumer backdrop as it undertakes a portfolio review under interim CEO Kirk Perry.

Via Stocktwits

Topics Economy Government Lawsuit

These S&P500 stocks are the most active in today's session ↗

September 23, 2025

Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Tuesday and uncover the stocks that are leading the way in terms of trading volume and market...

Via Chartmill

Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below. ↗

September 23, 2025

In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Tuesday's session.

Via Chartmill

What's Going On With Kenvue Stock Tuesday? ↗

September 23, 2025

Kenvue shares are trading higher Tuesday despite Trump saying the Food and Drug Administration will notify physicians that use of acetaminophen or Tylenol during pregnancy could be associated with...

Via Benzinga

Topics Government

Kenvue On Track To Bounce Back From Record Lows — What’s Driving Stock Higher In Premarket? ↗

September 23, 2025

Many doctors reportedly disagreed with the Trump administration’s Tylenol claims and warned that these unfounded claims would likely impair maternal health.

Via Stocktwits

Topics Government Lawsuit

Stock Market Today: Nasdaq Futures Rise, S&P 500 Slips Amid Mixed Trade—Kenvue, Micron Tech, Nvidia In Focus ↗

September 23, 2025

U.S. stock futures were fluctuating on Tuesday following Monday's record advances. Futures of major benchmark indices were mixed.

Via Benzinga

Topics Stocks

Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism ↗

September 23, 2025

Jim Cramer says Trump creates a "nightmare" for Kenvue after linking Tylenol to autism. Learn why KVUE stock is plunging amid lawsuit fears.

Via Benzinga

Topics Government Lawsuit

Nvidia’s $100B Bet in OpenAI Pushes Wall Street to Fresh Records ↗

September 23, 2025

Tech did the heavy lifting as Nvidia and Apple dragged indexes over the finish line; gold hit yet another all-time high while oil sagged. The Fed chorus grew louder and more discordant.

Via Chartmill

Topics Economy

Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check? ↗

September 23, 2025

Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks.

Via Stocktwits

Topics Government

Nvidia, Kenvue, Rivian, MicroCloud Hologram And Opendoor: Why These 5 Stocks Are On Investors' Radars Today ↗

September 22, 2025

U.S. stocks closed higher on Monday, with the Dow Jones Industrial Average edging up 0.14% to 46,381.54.

Via Benzinga

Topics Stocks

Which S&P500 stocks are moving on Monday? ↗

September 22, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.

Via Chartmill

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.